{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T05:26:31Z","timestamp":1785389191238,"version":"3.55.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2010,6,1]],"date-time":"2010-06-01T00:00:00Z","timestamp":1275350400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Bone"],"published-print":{"date-parts":[[2010,6]]},"DOI":"10.1016\/j.bone.2010.03.001","type":"journal-article","created":{"date-parts":[[2010,3,9]],"date-time":"2010-03-09T10:22:09Z","timestamp":1268130129000},"page":"1613-1619","source":"Crossref","is-referenced-by-count":38,"title":["Inhibition of RANKL increases the anti-tumor effect of the EGFR inhibitor panitumumab in a murine model of bone metastasis"],"prefix":"10.1016","volume":"46","author":[{"given":"Jude","family":"Canon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Bryant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine","family":"Roudier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Osgood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Coxon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Radinsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William C.","family":"Dougall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bone.2010.03.001_bib1","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1002\/(SICI)1097-0142(19971015)80:8+<1588::AID-CNCR9>3.0.CO;2-G","article-title":"Skeletal complications of malignancy","volume":"80","author":"Coleman","year":"1997","journal-title":"Cancer"},{"key":"10.1016\/j.bone.2010.03.001_bib2","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nature01658","article-title":"Osteoclast differentiation and activation","volume":"423","author":"Boyle","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.bone.2010.03.001_bib3","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0092-8674(00)81569-X","article-title":"Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation","volume":"93","author":"Lacey","year":"1998","journal-title":"Cell"},{"key":"10.1016\/j.bone.2010.03.001_bib4","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1101\/gad.12.9.1260","article-title":"Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification","volume":"12","author":"Bucay","year":"1998","journal-title":"Genes Dev"},{"key":"10.1016\/j.bone.2010.03.001_bib5","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0092-8674(00)80209-3","article-title":"Osteoprotegerin: a novel secreted protein involved in the regulation of bone density","volume":"89","author":"Simonet","year":"1997","journal-title":"Cell"},{"key":"10.1016\/j.bone.2010.03.001_bib6","first-page":"1655","article-title":"Mechanisms of bone metastasis","author":"Roodman","year":"2004"},{"key":"10.1016\/j.bone.2010.03.001_bib7","first-page":"4432","article-title":"Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis","volume":"61","author":"Morony","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/j.bone.2010.03.001_bib8","first-page":"S117","article-title":"Antitumor efficacy of the RANK ligand inhibitor OPG-Fc in the MDA-231 breast cancer and PC3 prostate cancer experimental osteolytic metastases models","volume":"20","author":"Miller","year":"2005","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2010.03.001_bib9","first-page":"S209","article-title":"OPG prevents bone destruction and decreases skeletal tumor burden in an experimental model of tumor metastasis to bone","volume":"15","author":"Morony","year":"2000","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2010.03.001_bib10","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.bone.2006.09.016","article-title":"Inhibition of bone resorption, rather than direct cytotoxicity, mediates the anti-tumour actions of ibandronate and osteoprotegerin in a murine model of breast cancer bone metastasis","volume":"40","author":"Zheng","year":"2007","journal-title":"Bone"},{"key":"10.1016\/j.bone.2010.03.001_bib11","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s10585-007-9127-1","article-title":"Inhibition of RANKL blocks skeletal tumor progression and improves survival in a mouse model of breast cancer bone metastasis","volume":"25","author":"Canon","year":"2008","journal-title":"Clin Exp Metastasis"},{"key":"10.1016\/j.bone.2010.03.001_bib12","doi-asserted-by":"crossref","first-page":"9542","DOI":"10.1158\/0008-5472.CAN-07-1046","article-title":"Accelerated bone resorption, due to dietary calcium deficiency, promotes breast cancer tumor growth in bone","volume":"67","author":"Zheng","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.bone.2010.03.001_bib13","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1056\/NEJMra0707704","article-title":"EGFR antagonists in cancer treatment","volume":"358","author":"Ciardiello","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bone.2010.03.001_bib14","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1677\/erc.1.00956","article-title":"Gefitinib inhibits the ability of human bone marrow stromal cells to induce osteoclast differentiation: implications for the pathogenesis and treatment of bone metastasis","volume":"12","author":"Normanno","year":"2005","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.bone.2010.03.001_bib15","doi-asserted-by":"crossref","first-page":"26656","DOI":"10.1074\/jbc.M705064200","article-title":"EGF-like ligands stimulate osteoclastogenesis by regulating expression of osteoclast regulatory factors by osteoblasts: implications for osteolytic bone metastases","volume":"282","author":"Zhu","year":"2007","journal-title":"J Biol Chem"},{"key":"10.1016\/j.bone.2010.03.001_bib16","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/j.ijrobp.2003.09.098","article-title":"Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody","volume":"58","author":"Foon","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.bone.2010.03.001_bib17","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1053\/sonc.2002.31522","article-title":"Therapeutic potential of ABX-EGF: a fully human anti-epidermal growth factor receptor monoclonal antibody for cancer treatment","volume":"29","author":"Lynch","year":"2002","journal-title":"Semin Oncol"},{"key":"10.1016\/j.bone.2010.03.001_bib18","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S1040-8428(00)00134-7","article-title":"Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy","volume":"38","author":"Yang","year":"2001","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.bone.2010.03.001_bib19","article-title":"ABX-EGF tumor penetration and EGFR saturation correlate with pharmacokinetic, pharmacodynamic and anti-tumor activity in an A431 xenograft model system","volume":"Vol. 45","author":"McDorman","year":"2004"},{"key":"10.1016\/j.bone.2010.03.001_bib20","doi-asserted-by":"crossref","first-page":"8463","DOI":"10.1128\/JVI.72.11.8463-8471.1998","article-title":"A third-generation lentivirus vector with a conditional packaging system","volume":"72","author":"Dull","year":"1998","journal-title":"J Virol"},{"key":"10.1016\/j.bone.2010.03.001_bib21","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1359\/jbmr.060706","article-title":"Mixed metastatic lung cancer lesions in bone are inhibited by noggin overexpression and Rank:Fc administration","volume":"21","author":"Feeley","year":"2006","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.bone.2010.03.001_bib22","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1158\/1535-7163.MCT-08-0046","article-title":"RANK ligand inhibition plus docetaxel improves survival and reduces tumor burden in a murine model of prostate cancer bone metastasis","volume":"7","author":"Miller","year":"2008","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.bone.2010.03.001_bib23","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1172\/JCI11685","article-title":"Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone","volume":"107","author":"Zhang","year":"2001","journal-title":"J Clin Invest"},{"key":"10.1016\/j.bone.2010.03.001_bib24","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1002\/pros.20744","article-title":"RANKL inhibition is an effective adjuvant for docetaxel in a prostate cancer bone metastases model","volume":"68","author":"Ignatoski","year":"2008","journal-title":"Prostate"},{"key":"10.1016\/j.bone.2010.03.001_bib25","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1210\/er.19.1.18","article-title":"Cancer and bone","volume":"19","author":"Guise","year":"1998","journal-title":"Endocr Rev"},{"key":"10.1016\/j.bone.2010.03.001_bib26","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1093\/jnci\/94.1.17","article-title":"Matrix metalloproteinase activity, bone matrix turnover, and tumor cell proliferation in prostate cancer bone metastasis","volume":"94","author":"Nemeth","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.bone.2010.03.001_bib27","first-page":"2554","article-title":"ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase","volume":"62","author":"Hirata","year":"2002","journal-title":"Cancer Res"},{"key":"10.1016\/j.bone.2010.03.001_bib28","first-page":"1936","article-title":"Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by antiangiogenic mechanisms","volume":"6","author":"Bruns","year":"2000","journal-title":"Clin Cancer Res"}],"container-title":["Bone"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328210004898?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S8756328210004898?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,6,2]],"date-time":"2020-06-02T17:38:50Z","timestamp":1591119530000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S8756328210004898"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,6]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2010,6]]}},"alternative-id":["S8756328210004898"],"URL":"https:\/\/doi.org\/10.1016\/j.bone.2010.03.001","relation":{},"ISSN":["8756-3282"],"issn-type":[{"value":"8756-3282","type":"print"}],"subject":[],"published":{"date-parts":[[2010,6]]}}}